{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Behr SC"],"funding":["UCSF Academic Senate","American Brain Tumor Association","National Institutes of Health"],"pagination":["93999"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6238742"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(21)"],"pubmed_abstract":["Noninvasive tools that target tumor cells could improve the management of glioma. Cancer generally has a high demand for Fe(III), an essential nutrient for a variety of biochemical processes. We tested whether 68Ga-citrate, an Fe(III) biomimetic that binds to apo-transferrin in blood, detects glioma in preclinical models and patients using hybrid PET/MRI. Mouse PET/CT studies showed that 68Ga-citrate accumulates in subcutaneous U87MG xenografts in a transferrin receptor-dependent fashion within 4 hours after injection. Seventeen patients with WHO grade III or IV glioma received 3.7-10.2 mCi 68Ga-citrate and were imaged with PET/MR 123-307 minutes after injection to establish that the radiotracer can localize to human tumors. Multiple contrast-enhancing lesions were PET avid, and tumor to a"],"journal":["JCI insight"],"pubmed_title":["Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR."],"pmcid":["PMC6238742"],"funding_grant_id":["N/A","P30CA082103","R01CA166766","P50CA097257","R01CA154561","R01CA17661","DG1700008","T32EB001631"],"pubmed_authors":["Behr SC","Gao KT","Nelson SJ","Wang YH","Ma W","Cha S","Evans MJ","Li Y","Seo Y","Moroz A","Lee JK","Hsiao JC","Wilson DM","Wei J","Villanueva-Meyer JE","Chang SM"],"additional_accession":[]},"is_claimable":false,"name":"Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR.","description":"Noninvasive tools that target tumor cells could improve the management of glioma. Cancer generally has a high demand for Fe(III), an essential nutrient for a variety of biochemical processes. We tested whether 68Ga-citrate, an Fe(III) biomimetic that binds to apo-transferrin in blood, detects glioma in preclinical models and patients using hybrid PET/MRI. Mouse PET/CT studies showed that 68Ga-citrate accumulates in subcutaneous U87MG xenografts in a transferrin receptor-dependent fashion within 4 hours after injection. Seventeen patients with WHO grade III or IV glioma received 3.7-10.2 mCi 68Ga-citrate and were imaged with PET/MR 123-307 minutes after injection to establish that the radiotracer can localize to human tumors. Multiple contrast-enhancing lesions were PET avid, and tumor to a","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Nov","modification":"2025-04-05T12:27:28.341Z","creation":"2019-03-27T00:08:32Z"},"accession":"S-EPMC6238742","cross_references":{"pubmed":["30385712"],"doi":["10.1172/jci.insight.93999"]}}